2 Registered trials

0 Recruiting

2 Unique sponsors

4 Unique IMPs

1 Commercial trials

Drug classes (ATC)

L Oncology (ATC L) 2

Mechanism of action (INN-stem analysis)

Monoclonal antibody (immune) 2 substances

Kinase inhibitor 1 substance

Checkpoint inhibitor (PD-1) 1 substance

Phase II

Phase I/II

Phase II: 1 Phase I/II: 1

Filter these 2 trials by country, sponsor, date range and more.

Phase II

1 trial

Phase I/II

1 trial

Sponsor activity

Sponsor	Type	Trials	Phases	Recruiting
Glaxosmithkline Research & Development Limited	Commercial	1	Phase I/II	0
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH	Academic	1	Phase II	0

New trials by year

2022

2025